Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neuronox is a purified botulinum toxin type A product developed and manufactured by Medytox, a South Korean biopharmaceutical company. It is indicated for the treatment of benign essential blepharospasm in adults and is widely used in both therapeutic and cosmetic settings to manage conditions such as spasticity (including spastic equinus gait in cerebral palsy), muscle stiffness (in elbow, wrist, fingers, ankle and toe muscles), cervical dystonia, overactive bladder symptoms, chronic migraine prevention, hyperhidrosis (excessive sweating), strabismus (squint), and reduction of facial wrinkles[1][3][4][5][6][8][9]. Neuronox works by blocking the release of acetylcholine at neuromuscular junctions through cleavage of SNARE proteins—specifically SNAP-25—resulting in temporary muscle paralysis or relaxation[7][9]. The onset of action typically occurs within 2–4 days with effects lasting up to 6–7 months depending on indication and patient characteristics[8][9]. Clinical studies have shown Neuronox to be non-inferior to other established botulinum toxin products such as Botox for efficacy and safety[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on neuronox.